Published in PLoS One on March 13, 2012
Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother (2012) 1.28
Geographically structured populations of Cryptococcus neoformans Variety grubii in Asia correlate with HIV status and show a clonal population structure. PLoS One (2013) 0.96
Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population. J Clin Microbiol (2012) 0.89
Molecular typing of clinical Cryptococcus neoformans isolates collected in Germany from 2004 to 2010. Med Microbiol Immunol (2014) 0.80
Molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii in China between 2007 and 2013 using multilocus sequence typing and the DiversiLab system. Eur J Clin Microbiol Infect Dis (2014) 0.80
Inhibition of bacterial and fungal pathogens by the orphaned drug auranofin. Future Med Chem (2016) 0.79
Activity of Scorpion Venom-Derived Antifungal Peptides against Planktonic Cells of Candida spp. and Cryptococcus neoformans and Candida albicans Biofilms. Front Microbiol (2016) 0.77
Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study. BMC Infect Dis (2015) 0.76
Phylogeographic Analysis of Blastomyces dermatitidis and Blastomyces gilchristii Reveals an Association with North American Freshwater Drainage Basins. PLoS One (2016) 0.75
Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease. Rev Inst Med Trop Sao Paulo (2017) 0.75
Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS (2009) 16.37
Global patterns of influenza a virus in wild birds. Science (2006) 13.80
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol (1982) 6.78
A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A (2004) 6.21
Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet (2004) 4.14
Hybrid genotypes in the pathogenic yeast Cryptococcus neoformans. Microbiology (2001) 3.27
Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother (2000) 3.08
Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol (2009) 2.80
Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol (1999) 2.78
In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis (2004) 2.69
Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental (pigeon excreta) and clinical sources in New York City. J Clin Microbiol (1994) 2.43
Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics (2001) 2.40
The biology of the Cryptococcus neoformans species complex. Annu Rev Microbiol (2006) 2.31
Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. J Clin Microbiol (1997) 2.19
Projecting global occurrence of Cryptococcus gattii. Emerg Infect Dis (2010) 1.78
Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis (2008) 1.72
Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol (2003) 1.70
Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother (2001) 1.70
In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates. Antimicrob Agents Chemother (1998) 1.69
Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol (2005) 1.61
Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res (2006) 1.54
Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol (2005) 1.53
Antifungal resistance in pathogenic fungi. Clin Infect Dis (2002) 1.52
Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev Iberoam Micol (2008) 1.48
Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother (2008) 1.47
Cryptococcus neoformans shows a remarkable genotypic diversity in Brazil. J Clin Microbiol (2004) 1.41
In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother (2010) 1.41
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother (2008) 1.40
Random amplified polymorphic DNA analysis of clinically and environmentally isolated Cryptococcus neoformans in Nagasaki. J Clin Microbiol (1995) 1.36
Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea. FEMS Yeast Res (2010) 1.32
Comparative analysis of the intergenic spacer regions and population structure of the species complex of the pathogenic yeast Cryptococcus neoformans. FEMS Yeast Res (2005) 1.17
Low diversity Cryptococcus neoformans variety grubii multilocus sequence types from Thailand are consistent with an ancestral African origin. PLoS Pathog (2011) 1.13
Drug resistance in Cryptococcus neoformans. Drug Resist Updat (1999) 1.13
Microsatellite based typing of Aspergillus fumigatus: strengths, pitfalls and solutions. J Microbiol Methods (2007) 1.10
Microsatellite typing of clinical and environmental Cryptococcus neoformans var. grubii isolates from Cuba shows multiple genetic lineages. PLoS One (2010) 1.10
Molecular typing of clinical and environmental Cryptococcus neoformans isolates in the Brazilian state Rio Grande do Sul. FEMS Yeast Res (2003) 1.04
In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol (2005) 0.98
The effect of HIV infection on adult meningitis in Indonesia: a prospective cohort study. AIDS (2009) 0.96
MLST versus microsatellites for typing Aspergillus fumigatus isolates. Med Mycol (2009) 0.93
High resolution genotyping of clinical Aspergillus flavus isolates from India using microsatellites. PLoS One (2011) 0.91
Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis. BMC Infect Dis (2010) 0.90
Human cryptococcosis: relationship of environmental and clinical strains of Cryptococcus neoformans var. neoformans from urban and rural areas. Mycopathologia (2005) 0.90
Most cases of cryptococcal meningitis in HIV-uninfected patients in Vietnam are due to a distinct amplified fragment length polymorphism-defined cluster of Cryptococcus neoformans var. grubii VN1. J Clin Microbiol (2010) 0.89
Serotype and PCR-fingerprints of clinical and environmental isolates of Cryptococcus neoformans in Chiang Mai, Thailand. Mycopathologia (2004) 0.87
Survival time of HIV-infected patients with cryptococcal meningitis. J Med Assoc Thai (2007) 0.86
Molecular typing and antifungal susceptibility of clinical and environmental Cryptococcus neoformans species complex isolates in Goiania, Brazil. Mycoses (2009) 0.84
Phenotypic switching and genetic diversity of Cryptococcus neoformans. J Clin Microbiol (2001) 0.82
Invasive fungal infections among inpatients with acquired immune deficiency syndrome at a Chinese university hospital. Mycoses (2007) 0.79
The amsterdam declaration on fungal nomenclature. IMA Fungus (2011) 5.86
European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother (2003) 4.08
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med (2016) 3.59
Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1β via a noncanonical caspase-8 inflammasome. Nat Immunol (2012) 2.94
In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother (2003) 2.80
Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med Mycol (2009) 2.80
Presence of a novel DNA methylation enzyme in methicillin-resistant Staphylococcus aureus isolates associated with pig farming leads to uninterpretable results in standard pulsed-field gel electrophoresis analysis. J Clin Microbiol (2006) 2.43
Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of Aspergillus fumigatus isolates. J Clin Microbiol (2005) 2.36
In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother (2002) 2.36
Dandruff-associated Malassezia genomes reveal convergent and divergent virulence traits shared with plant and human fungal pathogens. Proc Natl Acad Sci U S A (2007) 2.18
Skin diseases associated with Malassezia species. J Am Acad Dermatol (2004) 2.14
Therapeutic drug monitoring of voriconazole. Ther Drug Monit (2008) 2.09
The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med (2012) 1.94
Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis. J Clin Microbiol (2006) 1.87
New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis (2013) 1.86
In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother (2003) 1.85
The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc Natl Acad Sci U S A (2009) 1.84
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping. J Clin Microbiol (2004) 1.73
Emergence of azole-resistant aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog (2013) 1.70
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob Agents Chemother (2009) 1.69
The reach of the genome signature in prokaryotes. BMC Evol Biol (2006) 1.69
Interlaboratory evaluation of different extraction and real-time PCR methods for detection of Coxiella burnetii DNA in serum. J Clin Microbiol (2010) 1.65
Multigenotype Q fever outbreak, the Netherlands. Emerg Infect Dis (2009) 1.63
Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother (2012) 1.62
Selective C-Rel activation via Malt1 controls anti-fungal T(H)-17 immunity by dectin-1 and dectin-2. PLoS Pathog (2011) 1.62
Molecular epidemiology of Aspergillus fumigatus isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. J Clin Microbiol (2003) 1.59
Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother (2011) 1.56
Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis (2013) 1.56
Fungal rhinosinusitis: a categorization and definitional schema addressing current controversies. Laryngoscope (2009) 1.54
Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res (2006) 1.54
Fermentation characteristics of yeasts isolated from traditionally fermented masau (Ziziphus mauritiana) fruits. Int J Food Microbiol (2013) 1.54
Sequence analysis of the ribosomal DNA intergenic spacer 1 regions of Trichosporon species. J Clin Microbiol (2002) 1.52
MRSA genotypes in Turkey: persistence over 10 years of a single clone of ST239. J Infect (2009) 1.50
RespiFinder: a new multiparameter test to differentially identify fifteen respiratory viruses. J Clin Microbiol (2008) 1.49
Genotypic diversity of Coxiella burnetii in the 2007-2010 Q fever outbreak episodes in The Netherlands. J Clin Microbiol (2011) 1.49
Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother (2010) 1.49
Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob Agents Chemother (2007) 1.48
Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother (2010) 1.48
Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev Iberoam Micol (2008) 1.48
Protein binding: do we ever learn? Antimicrob Agents Chemother (2011) 1.46
Pneumolysin is a key factor in misidentification of macrolide-resistant Streptococcus pneumoniae and is a putative virulence factor of S. mitis and other streptococci. J Clin Microbiol (2004) 1.44
Constructing level-2 phylogenetic networks from triplets. IEEE/ACM Trans Comput Biol Bioinform (2009) 1.43
Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. Clin Pharmacol Ther (2002) 1.41
In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother (2010) 1.41
Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet (2004) 1.40
In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother (2008) 1.40
Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR₃₄/L98H mutations in the cyp51A gene in India. PLoS One (2012) 1.38
Burkholderia fungorum septicemia. Emerg Infect Dis (2005) 1.37
Prevalence of Helicobacter pylori vacA, cagA, cagE, iceA and babA2 genotypes in Thai dyspeptic patients. Int J Infect Dis (2007) 1.37
Allergic bronchopulmonary mycosis due to fungi other than Aspergillus: a global overview. Crit Rev Microbiol (2013) 1.37
Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. Chest (2007) 1.35
Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med Mycol (2005) 1.34
Epidemic genotype of Coxiella burnetii among goats, sheep, and humans in the Netherlands. Emerg Infect Dis (2012) 1.32
AIDS patient death caused by novel Cryptococcus neoformans x C. gattii hybrid. Emerg Infect Dis (2008) 1.31
Zygomycosis--a case report and overview of the disease in India. Mycoses (2007) 1.30
Cryptococcus gattii genotype VGIIa infection in man, Japan, 2007. Emerg Infect Dis (2010) 1.30
High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother (2011) 1.27
Fast, noninvasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol (2002) 1.26
Sporangiospore size dimorphism is linked to virulence of Mucor circinelloides. PLoS Pathog (2011) 1.26
Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat (2012) 1.24
Evidence for genetic differentiation and variable recombination rates among Dutch populations of the opportunistic human pathogen Aspergillus fumigatus. Mol Ecol (2011) 1.24
Two new lipid-dependent Malassezia species from domestic animals. FEMS Yeast Res (2007) 1.23
Spectrum of fungal rhinosinusitis; histopathologist's perspective. Histopathology (2009) 1.22
Phylogenomics reveal a robust fungal tree of life. FEMS Yeast Res (2006) 1.19
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp. Antimicrob Agents Chemother (2010) 1.19
Identification and typing of Malassezia species by amplified fragment length polymorphism and sequence analyses of the internal transcribed spacer and large-subunit regions of ribosomal DNA. J Clin Microbiol (2004) 1.19
Environmental prevalence of Cryptococcus neoformans and Cryptococcus gattii in India: an update. Crit Rev Microbiol (2011) 1.17
Comparative analysis of the intergenic spacer regions and population structure of the species complex of the pathogenic yeast Cryptococcus neoformans. FEMS Yeast Res (2005) 1.17
Molecular characterization and in vitro antifungal susceptibility profile of Schizophyllum commune, an emerging basidiomycete in bronchopulmonary mycoses. Antimicrob Agents Chemother (2013) 1.17
Candida auris candidemia in Kuwait, 2014. Emerg Infect Dis (2015) 1.16
Molecular epidemiology of Aspergillus fumigatus isolates harboring the TR34/L98H azole resistance mechanism. J Clin Microbiol (2012) 1.16
Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands. J Antimicrob Chemother (2010) 1.16
Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011-2013. Emerg Infect Dis (2014) 1.15
Genomic insights into the atopic eczema-associated skin commensal yeast Malassezia sympodialis. MBio (2013) 1.15
Ancient dispersal of the human fungal pathogen Cryptococcus gattii from the Amazon rainforest. PLoS One (2013) 1.15
Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother (2012) 1.14
Low diversity Cryptococcus neoformans variety grubii multilocus sequence types from Thailand are consistent with an ancestral African origin. PLoS Pathog (2011) 1.13
Long-distance dispersal and recombination in environmental populations of Cryptococcus neoformans var. grubii from India. Microbiology (2008) 1.13
Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol (2002) 1.13